Del Labs sales and earnings
This article was originally published in The Tan Sheet
Executive SummaryNet sales jump 12.8% to $332.7 mil. in 2001, driven in part by "double-digit sales increases" in Orajel line, strong gains in cosmetics segment, firm announces Feb. 21. Also, Dermarest "continues as the number one brand of OTC psoriasis treatments," Uniondale, N.Y.-based Del notes. Net earnings more than doubled to $9.8 mil. for the year. Fourth quarter sales were up 16.4% to $85.7 mil., while earnings soared 149.6% to $2.8 mil...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.